177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
A phase 1/2 trial of 177Lu-BetaBart in prostate cancer, colorectal cancer, non-small-cell lung cancer, ovarian cancer, cervical cancer and endometrial cancer, run by Radiopharm Theranostics, Ltd, now recruiting.
Overview
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07189871 by Radiopharm Theranostics, Ltd, with 61 participants planned, started 2026-02-23 and due to reach its primary completion in 2027-12. Interventions recorded: 177Lu-BetaBart.
Similar pages
not linked directly; found by shared links- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Endometrial cancer, Ovarian cancer, Prostate cancer, Colorectal cancer and the tag pipeline.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Endometrial cancer, Ovarian cancer, Prostate cancer, Colorectal cancer and the tag pipeline.
- Trial[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Shares Medpace, Ovarian cancer, Colorectal cancer and the tag pipeline.
- Trial[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Shares Medpace, Ovarian cancer, Colorectal cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Shares Endometrial cancer, Ovarian cancer, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialThe OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Shares Medpace and the tag pipeline.
- TrialAzeliragon in MGMT Unmethylated Glioblastoma
Shares Medpace and the tag pipeline.
- TrialA Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Shares Endometrial cancer, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.